The mechanism of action for the combined treatment of anti-CTLA-4 antibody and metformin in tumors involves the alleviation of T-cell inhibition, enhancement of T-cell antitumor immune activity, and regulation of tumor cell metabolism, achieving a synergistic antitumor effect. The gene discussed is CTLA4; the disease is neoplasm.